Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
This membrane protein is Human TNF-alpha (77-233). It has been tested in SDS-PAGE, ELISA, Cell based assay, SPR, SEC-MALS. We provide this protein to facilitate your membrane protein antibody discovery and development.
Product Specifications
Host Species
Human
Target Protein
TNF-alpha
Protein Length
ECD
Molecular Weight
The protein has a calculated MW of 17.4 kDa. The protein migrates as 17 kDa and 18 kDa under reducing (R) condition (SDS-PAGE).
Sequence
AA Val 77 - Leu 233 (Accession # P01375-1).
Product Description
Activity
Yes
Application
SDS-PAGE, ELISA, Cell based assay, SPR, SEC-MALS
Expression Systems
HEK293
Tag
No tag
Protein Format
Soluble
Reconstitution
Please see Certificate of Analysis for specific instructions.
Endotoxin
<0.1 EU/μg by the LAL method
Purity
>95% as determined by SDS-PAGE. >95% as determined by SEC-MALS.
Buffer
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Target
Target Protein
TNF-alpha
Full Name
tumor necrosis factor
Introduction
This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, psoriasis, rheumatoid arthritis ankylosing spondylitis, tuberculosis, autosomal dominant polycystic kidney disease, and cancer. Mutations in this gene affect susceptibility to cerebral malaria, septic shock, and Alzheimer disease. Knockout studies in mice also suggested the neuroprotective function of this cytokine.